{
  "id": 1243047,
  "title": "Eli Lilly’s Weight-Loss Pill Just Got Its First Foothold in Europe",
  "url": "https://urgent.news/2026/08/15/eli-lillys-weight-loss-pill-just-got-its-first-foothold-in-europe",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-15T10:30:07.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-weight-loss-pill-103007818.html"
  },
  "original_language": "en",
  "account": "Eli Lilly's weight-loss drug, Foundayo, has received regulatory approval in the United Kingdom, marking its first foothold in Europe. The drug, a non-peptide GLP-1 receptor agonist tablet, was granted authorization by the UK's Medicines and Healthcare Products Regulatory Agency. This approval allows Foundayo to be taken as a daily pill, without food or water restrictions, making it more convenient than other oral peptide alternatives. Clinical data supports the approval, showing that participants on a 36 mg dose lost an average of 11.2% of their body weight, compared to 2.1% for those on a placebo. However, Foundayo is not yet available through the NHS in the UK, and its journey to the larger market depends on the National Institute for Health and Care Excellence to complete a cost-effectiveness study. This approval places Eli Lilly in direct competition with Novo Nordisk's oral weight-loss drug, Wegovy, which was approved in the UK in June. Both companies will likely compete based on efficacy, tolerability, pricing, and supply. The approval is seen as a positive for Eli Lilly's long-term market leadership in the metabolic health sector, with a forward P/E ratio of 25.99x indicating investor confidence in its dual-engine growth narrative. Investors should watch for the November 18 NICE payment ruling as a key driver for near-term trading direction.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}